McKesson Corp Enters Material Definitive Agreement
Ticker: MCK · Form: 8-K · Filed: Apr 6, 2026 · CIK: 0000927653
Sentiment: neutral
Topics: debt, financing, material-agreement
TL;DR
McKesson just signed a big new credit deal, expect financial moves.
AI Summary
On April 1, 2026, McKesson Corporation entered into a material definitive agreement, specifically an executed credit agreement. This agreement likely involves the creation of a direct financial obligation or an obligation under an off-balance sheet arrangement for the registrant. The filing also includes financial statements and exhibits related to this agreement.
Why It Matters
This filing indicates a significant new financial commitment or arrangement for McKesson Corporation, which could impact its financial obligations and operational flexibility.
Risk Assessment
Risk Level: medium — Entering into new material definitive agreements, especially credit agreements, can introduce financial obligations and potential risks depending on the terms.
Key Players & Entities
- McKesson Corporation (company) — Filer
- 0000927653 (company) — CIK
- 2026-04-01 (date) — Period of Report
- 2026-04-06 (date) — Filing Date
FAQ
What is the nature of the material definitive agreement McKesson Corporation entered into?
The filing indicates an 'executed credit agreement' as a material definitive agreement.
When was this material definitive agreement entered into?
The period of report for this agreement is April 1, 2026.
What are the specific financial obligations created by this agreement?
The filing states it is the 'Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant', but specific details of the obligation are not provided in the summary.
What exhibits are included with this 8-K filing?
The filing includes an executed credit agreement (EX-10.1) and other related documents like XBRL instance documents and graphics.
What is McKesson Corporation's primary business according to the filing?
McKesson Corporation's SIC code is 5122, indicating Wholesale-Drugs, Proprietaries & Druggists' Sundries.
Filing Stats: 1,073 words · 4 min read · ~4 pages · Grade level 11.4 · Accepted 2026-04-06 08:03:56
Key Financial Figures
- $0.01 — ange on which registered Common stock, $0.01 par value MCK New York Stock Exchange
- $750.0 million — nd collateral agent providing for (i) a $750.0 million senior secured term "A" loan facility d
- $250.0 million — (the "Term Loan A-1 Facility"), (ii) a $250.0 million senior secured term "A" loan facility d
- $1,000.0 million — e "Term Loan A Facilities") and (iii) a $1,000.0 million senior secured revolving credit facilit
Filing Documents
- mck-20260401.htm (8-K) — 34KB
- mck_ex101executedcreditagr.htm (EX-10.1) — 2261KB
- mck-20260401_g1.jpg (GRAPHIC) — 11KB
- 0000927653-26-000045.txt ( ) — 2904KB
- mck-20260401.xsd (EX-101.SCH) — 3KB
- mck-20260401_def.xml (EX-101.DEF) — 16KB
- mck-20260401_lab.xml (EX-101.LAB) — 29KB
- mck-20260401_pre.xml (EX-101.PRE) — 17KB
- mck-20260401_htm.xml (XML) — 5KB
01 Entry into a Material Definitive Agreement
Item 1.01 Entry into a Material Definitive Agreement. On April 1, 2026, certain of McKesson Corporation's (the "Company") subsidiaries, including McKesson Medical-Surgical Top Holdings, Inc. (the "Borrower"), entered into a credit agreement (the "Credit Agreement") with the lenders and issuing banks party thereto and JPMorgan Chase Bank, N.A., as administrative agent and collateral agent providing for (i) a $750.0 million senior secured term "A" loan facility due 2031 (the "Term Loan A-1 Facility"), (ii) a $250.0 million senior secured term "A" loan facility due 2028 (the "Term Loan A-2 Facility" and, together with the Term Loan A-1 Facility, the "Term Loan A Facilities") and (iii) a $1,000.0 million senior secured revolving credit facility (the "Revolving Credit Facility" and, together with the Term Loan A Facilities, the "Senior Secured Credit Facilities"). The Revolving Credit Facility matures on April 1, 2031. The Borrower and certain other subsidiaries of the Company also entered into security, guaranty and other related agreements in connection with the Credit Agreement. Borrowings under the Term Loan A Facilities will bear interest at a rate selected by Borrower equal to either (i) the Adjusted Term SOFR Rate (as defined in the Credit Agreement), plus an applicable margin equal to 1.250% per annum or (ii) the Base Rate (as defined in the Credit Agreement), plus an applicable margin equal to 0.250% per annum. The Borrower selected an initial interest rate equal to the Adjusted Term SOFR Rate plus the applicable margin of 1.250% per annum. Borrowings under the Revolving Credit Facility will bear interest at a rate selected by Borrower at a rate initially equal to either (x) the Term Benchmark Rate (as defined in the Credit Agreement), plus an applicable margin equal to 1.250% per annum or (y) the Base Rate, plus an applicable margin equal to 0.250% per annum, in each case until financial statements for the fiscal quarter ending June 30, 2026 have been delive
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 10.1 Credit Agreement, dated as of April 1, 2026, among McKesson Medical-Surgical Top Holdings Inc., as borrower, the lenders, the issuing banks party thereto, JPMorgan Chase Bank, N.A., as administrative agent and collateral agent, and the other parties thereto. 104 Cover Page Interactive Data File - the cover page iXBRL tags are embedded within the Inline XBRL document
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: April 6, 2026 McKesson Corporation By: /s/ Britt J. Vitalone Britt J. Vitalone Executive Vice President and Chief Financial Officer